Patents by Inventor Joel Stevens

Joel Stevens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180273464
    Abstract: This invention describes the synthesis and pharmacologic activity of n=2, n=3, n=4, n=5, and n=6 D-lactic acid oligomers. D-lactic acid dimer has pharmacologic activity and sequesters L-lactate, and the other D-lactic acid oligomers have no activity in vitro, but may have pharmacologic activity in vivo as prodrugs of D-lactic acid dimer.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Joel Steven Goldberg, David Martin Gooden
  • Publication number: 20180235457
    Abstract: The present disclosure describes systems and method for generating surgical maps that provide a surgeon with information regarding the placement of features of interest. More particularly, the system is configured to display optical coherence tomography (OCT) images to a medical professional. The medical professional can select anatomical features, biomarkers, and other features of interest within each of the OCT images. The system can then translate the location of the features of interest within the OCT images to an en face image to generate a map of the features that the medical professional can use for surgical guidance.
    Type: Application
    Filed: February 24, 2016
    Publication date: August 23, 2018
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, The Regents of the University of Michigan
    Inventors: Lawrence E. KAGEMANN, JR., Joel Steven SCHUMAN, Sayoko Eileen MOROI
  • Publication number: 20180218210
    Abstract: Aspects of the subject disclosure are directed towards safely projecting a diffracted light pattern, such as in an infrared laser-based projection/illumination system. Non-diffracted (zero-order) light is refracted once to diffuse (defocus) the non-diffracted light to an eye safe level. Diffracted (non-zero-order) light is aberrated twice, e.g., once as part of diffraction by a diffracting optical element encoded with a Fresnel lens (which does not aberrate the non-diffracted light), and another time to cancel out the other aberration; the two aberrations may occur in either order. Various alternatives include upstream and downstream positioning of the diffracting optical element relative to a refractive optical element, and/or refraction via positive and negative lenses.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Inventors: Andreas Georgiou, Joel Steven Kollin, Sing Bing Kang
  • Patent number: 10034895
    Abstract: At equimolar concentrations, D-lactic acid dimer is more cytotoxic than L-lactic acid when directly applied to human HeLa cells in culture. The cytotoxicity of D-lactic acid dimer is an independent effect exclusive of the lower pH when applied to cancer cells in culture. At equimolar concentrations, D-lactic acid dimer is less cytotoxic than L-lactic acid when applied to normal human fibroblasts in culture. D-lactic acid dimer is cytotoxic when applied to human retinoblastoma cells in culture in a dose-dependent fashion. The experimental data supports the cytotoxic mechanism of D-lactic acid dimer via the Warburg effect.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 31, 2018
    Inventors: Joel Steven Goldberg, Joe Brice Weinberg
  • Publication number: 20180188687
    Abstract: Examples are disclosed that relate to holographic near-eye display systems. One example provides a near-eye display device, comprising a diverging light source, an image producing dynamic digital hologram panel configured to receive light from the diverging light source and form an image. The near-eye display device also includes and a combiner comprising a holographic optical element positioned to receive light from the dynamic digital hologram panel and to redirect the light toward an eyebox, the holographic optical element being positioned between the eyebox and a view of an external environment to combine a view of the image formed by the dynamic digital hologram panel and the view of the external environment.
    Type: Application
    Filed: March 8, 2017
    Publication date: July 5, 2018
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Andrew Maimone, Andreas Georgiou, Joel Steven Kollin
  • Publication number: 20180188688
    Abstract: Examples are disclosed that relate to holographic near-eye display systems. One example provides a near-eye display device, comprising a diverging light source, an image producing dynamic digital hologram panel configured to receive light from the diverging light source and form an image. The near-eye display device also includes and a combiner comprising a holographic optical element positioned to receive light from the dynamic digital hologram panel and to redirect the light toward an eyebox, the holographic optical element being positioned between the eyebox and a view of an external environment to combine a view of the image formed by the dynamic digital hologram panel and the view of the external environment.
    Type: Application
    Filed: January 3, 2017
    Publication date: July 5, 2018
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Andrew Maimone, Andreas Georgiou, Joel Steven Kollin
  • Patent number: 10004766
    Abstract: Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 26, 2018
    Assignee: University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Yiqin Du, James L. Funderburgh, Joel Steven Schuman
  • Publication number: 20180158182
    Abstract: The present invention is directed to systems and methods for generating virtually averaged optical coherence tomography (OCT) images. An illustrative method can include receiving an image, identifying a first voxel of the image, and selecting a plurality of local voxels of the image. Each of the plurality of local voxels is within a defined region of the first voxel. The values of the plurality of local voxels can indicate an appearance of the local voxels in the image.
    Type: Application
    Filed: April 28, 2016
    Publication date: June 7, 2018
    Applicant: University of Pittsburgh - Of The Commonwealth System of Higher Education
    Inventors: Hiroshi ISHIKAWA, Chieh-Li Chen, Joel Steven Schuman, Chaim-Gadi Wollstein
  • Publication number: 20180140184
    Abstract: The innovation provides for a system and method available to image and visualize the palisades of Vogt via a non-contact process, analyze the image volumes acquired, evaluate the status of the palisades of Vogt from the data represented therein, and display the data in real-time or as a part of a medical record for ongoing consideration and evaluation.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 24, 2018
    Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Kira Lynn Lathrop, Joel Steven Schuman, Lawrence Edward Kagemann
  • Publication number: 20180120563
    Abstract: Examples are disclosed that relate to a near-eye display device including a holographic display system. The holographic display system includes a light source configured to emit light that is converging or diverging, a waveguide configured to be positioned in a field of view of a user's eye, and a digital dynamic hologram configured to receive the light, and project the light into the waveguide such that the light propagates through the waveguide.
    Type: Application
    Filed: June 15, 2017
    Publication date: May 3, 2018
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Joel Steven KOLLIN, Andrew MAIMONE, Steven John ROBBINS, Eliezer GLIK, Andreas GEORGIOU, Xinye LOU
  • Patent number: 9959465
    Abstract: Aspects of the subject disclosure are directed towards safely projecting a diffracted light pattern, such as in an infrared laser-based projection/illumination system. Non-diffracted (zero-order) light is refracted once to diffuse (defocus) the non-diffracted light to an eye safe level. Diffracted (non-zero-order) light is aberrated twice, e.g., once as part of diffraction by a diffracting optical element encoded with a Fresnel lens (which does not aberrate the non-diffracted light), and another time to cancel out the other aberration; the two aberrations may occur in either order. Various alternatives include upstream and downstream positioning of the diffracting optical element relative to a refractive optical element, and/or refraction via positive and negative lenses.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: May 1, 2018
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Andreas Georgiou, Joel Steven Kollin, Sing Bing Kang
  • Publication number: 20180085394
    Abstract: At equimolar concentrations, D-lactic acid dimer is more cytotoxic than L-lactic acid when directly applied to human HeLa cells in culture. The cytotoxicity of D-lactic acid dimer is an independent effect exclusive of the lower pH when applied to cancer cells in culture. At equimolar concentrations, D-lactic acid dimer is less cytotoxic than L-lactic acid when applied to normal human fibroblasts in culture. D-lactic acid dimer is cytotoxic when applied to human retinoblastoma cells in culture in a dose-dependent fashion. The experimental data supports the cytotoxic mechanism of D-lactic acid dimer via the Warburg effect.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Inventors: Joel Steven Goldberg, Joe Brice Weinberg
  • Publication number: 20180081322
    Abstract: A head-mounted display device comprises a rendering engine configured to generate a hologram representative of a three-dimensional object. The hologram includes depth information that causes the three-dimensional object to be rendered with a focus that is determined by the depth information. The device also includes a spatial light modulator that modulates light from a light source as indicated by the hologram. A switchable hologram comprises multiple stacked switchable gratings. Each of the stacked switchable gratings is associated with one or more resulting exit pupil locations on a viewing surface. The system also comprises an eye tracker configured to map a viewing direction of a user's eye to a viewing location on the viewing surface. A processor is configured to activate a particular switchable grating within the switchable transmission hologram that is associated with an exit pupil location that aligns with the viewing location.
    Type: Application
    Filed: September 16, 2016
    Publication date: March 22, 2018
    Inventors: Steven John Robbins, Andrew Maimone, Andreas Georgiou, Joel Steven Kollin
  • Publication number: 20180035842
    Abstract: A lid assembly that can be placed on a pan having a bottom surface that is configured for placement on a burner of the stove top with one or more foods to be cooked supported above an inner bottom surface of the pan by a rack. The lid assembly covers the pan and thereby encloses the one or more foods to be cooked and the rack within a cavity defined by the pan and the lid assembly. An air flow generator mounted on a shaft that extends through a cover portion of the lid from a motor disposed on an opposite side of the cover portion rotates the shaft to produce airflow within the cavity. The lid assembly cooks foods in less time and using less energy than normally required with a conventional oven.
    Type: Application
    Filed: June 27, 2017
    Publication date: February 8, 2018
    Inventors: William C. Stumphauzer, Joel Steven Marks
  • Publication number: 20170367573
    Abstract: The innovation provides for a system and method available to image and visualize the palisades of Vogt via a non-contact process, analyze the image volumes acquired, evaluate the status of the palisades of Vogt from the data represented therein, and display the data in real-time or as a part of a medical record for ongoing consideration and evaluation.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 28, 2017
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: KIRA LYNN LATHROP, JOEL STEVEN SCHUMAN, LAWRENCE EDWARD KAGEMANN
  • Patent number: 9844315
    Abstract: The present disclosure is directed to systems and methods for normalizing an image of an eye among multiple optical coherence tomography (OCT) devices. The system can receive an OCT image and generate a normalized OCT image. The system is configured to normalize a sample density of the received image, normalize an amount of noise using a suitable noise reduction technique, normalize a distribution of signal amplitudes of the image, and then normalize a signal quality of the image. The resulting normalized image of the eye can then be used in the comparison among OCT images taken from multiple OCT devices.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: December 19, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Chieh-Li Chen, Hiroshi Ishikawa, Joel Steven Schuman, Chaim-Gadi Wollstein
  • Publication number: 20170299579
    Abstract: The vitelline membrane of an egg is a novel, inexpensive and useful model of the human blood brain barrier (BBB). FD&C Blue #1, FD&C Red #40, FD&C Red #3, quinine and fluorescein do not cross the vitelline membrane and do not cross the human BBB. Ethanol, diethyl ether, 2-chloroprocaine and acetaminophen, cross the vitelline membrane and are known to cross the human BBB. Using the vitelline membrane, as model of the human BBB, may decrease the time and cost of discovering lead drugs for the treatment of central nervous system diseases.
    Type: Application
    Filed: October 28, 2016
    Publication date: October 19, 2017
    Inventor: Joel Steven Goldberg
  • Publication number: 20170253854
    Abstract: A method of preparing a functional trabecular meshwork (TM) cell from adipose-derived stem cells is provided. Methods of treating glaucoma, implanting trabecular meshwork (TM) cells, or repairing or regenerating the aqueous outflow pathway of an eye of a patient also are provided.
    Type: Application
    Filed: March 2, 2017
    Publication date: September 7, 2017
    Inventors: Yiqin Du, Joel Steven Schuman
  • Publication number: 20170189709
    Abstract: Intractable pain is a horrific cause of world-wide suffering. Nervous system excitation is a hallmark of intractable pain and lesioning of excited pathways and structures can produce sustained analgesia. This invention shows that red blood cells exposed to changing magnetic fields are disrupted, releasing hemoglobin, and that this effect is related to the dose (conformation, frequency, strength and duration) of the changing magnetic fields. Extrapolating these finding to the nervous system, transcranial magnetic lesioning of select areas of the central nervous system, in particular the anterior cingulate cortex or anterior cingulate cortices, can provide relief for patients who suffer devastating intractable pain. The changing magnetic fields are produced by electrical current through a Helmholtz coil with a soft iron core.
    Type: Application
    Filed: March 20, 2017
    Publication date: July 6, 2017
    Inventor: Joel Steven Goldberg
  • Publication number: 20170165371
    Abstract: Esters prodrugs that cross the blood brain barrier can be ideal drugs for treatment of diseases of the central nervous system because the cerebral spinal fluid contains an abundance of esterases. The prodrug can be hydrolyzed into an active drug and a metabolite such as cholesterol that is known to be non-toxic and is familiar to the central nervous system. This invention describes a modification of the Fischer-Speier or Fischer esterification reaction in which one reagent is lipophilic and the other reagent is hydrophilic. The reaction occurs in a heterogeneous mixture. The preferred catalyst is 1.0 M hydrochloric acid and the preferred solvent is acetone. The presence of ester synthesis was confirmed by the hydroxamic acid-ferric perchlorate reaction. The synthesis can be conducted without chemical scaffolds and without protecting functional groups.
    Type: Application
    Filed: February 22, 2017
    Publication date: June 15, 2017
    Inventor: Joel Steven Goldberg